[go: up one dir, main page]

WO2010013012A3 - Hypothermia inducing polypeptides and uses thereof - Google Patents

Hypothermia inducing polypeptides and uses thereof Download PDF

Info

Publication number
WO2010013012A3
WO2010013012A3 PCT/GB2009/001885 GB2009001885W WO2010013012A3 WO 2010013012 A3 WO2010013012 A3 WO 2010013012A3 GB 2009001885 W GB2009001885 W GB 2009001885W WO 2010013012 A3 WO2010013012 A3 WO 2010013012A3
Authority
WO
WIPO (PCT)
Prior art keywords
hypothermia
fragment
fusion
variant
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2009/001885
Other languages
French (fr)
Other versions
WO2010013012A9 (en
WO2010013012A4 (en
WO2010013012A2 (en
Inventor
Carin SJÖLUND
Björn Ulrik WALSE
Tadeusz Wieloch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LUND UNIVERSITY BIOSCIENCE AB
Original Assignee
LUND UNIVERSITY BIOSCIENCE AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LUND UNIVERSITY BIOSCIENCE AB filed Critical LUND UNIVERSITY BIOSCIENCE AB
Publication of WO2010013012A2 publication Critical patent/WO2010013012A2/en
Publication of WO2010013012A3 publication Critical patent/WO2010013012A3/en
Publication of WO2010013012A4 publication Critical patent/WO2010013012A4/en
Publication of WO2010013012A9 publication Critical patent/WO2010013012A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a polypeptide capable of binding to a receptor for glucagon-like peptide-1 (GLP-1) for use in inducing or maintaining hypothermia in a subject in need thereof, wherein the polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 1 or a fragment, variant, derivative or fusion thereof (or a fusion of said fragment, variant or derivative) which retains the hypothermia-inducing activity of said amino acid sequence. The invention further provides pharmaceutical compositions comprising the polypeptides of the invention, together with methods and uses of the same.
PCT/GB2009/001885 2008-08-01 2009-07-31 Novel polypeptides and uses thereof Ceased WO2010013012A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0801752-7 2008-08-01
SE0801752 2008-08-01
US19179108P 2008-09-12 2008-09-12
US61/191,791 2008-09-12

Publications (4)

Publication Number Publication Date
WO2010013012A2 WO2010013012A2 (en) 2010-02-04
WO2010013012A3 true WO2010013012A3 (en) 2010-04-01
WO2010013012A4 WO2010013012A4 (en) 2010-06-10
WO2010013012A9 WO2010013012A9 (en) 2010-08-12

Family

ID=41463119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/001885 Ceased WO2010013012A2 (en) 2008-08-01 2009-07-31 Novel polypeptides and uses thereof

Country Status (1)

Country Link
WO (1) WO2010013012A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010120476A2 (en) * 2009-04-01 2010-10-21 Amylin Pharmaceuticals, Inc. N-terminus conformationally constrained glp-1 receptor agonist compounds
EP2718318B1 (en) 2011-06-10 2018-07-25 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
UA114709C2 (en) 2011-06-17 2017-07-25 Ханмі Сайенс Ко., Лтд. CONJUGATE CONTAINING OXYNTOMODULIN DERIVATIVES, THE FACILITY OF THE IMMUNOGLOBULIN AND THE NON-REPTIDYL POLYMER, AND ITS APPLICATION
KR101968344B1 (en) 2012-07-25 2019-04-12 한미약품 주식회사 A composition for treating hyperlipidemia comprising oxyntomodulin analog
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
KR101993393B1 (en) 2012-11-06 2019-10-01 한미약품 주식회사 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
SG10201602801YA (en) 2012-11-06 2016-05-30 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
SI2934568T1 (en) 2012-12-21 2018-03-30 Sanofi Dual glp1/gip or trigonal glp1/gip/glucagon agonists
TW201609797A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists
TW201609796A (en) 2013-12-13 2016-03-16 賽諾菲公司 Non-acylated EXENDIN-4 peptide analogues
TW201609795A (en) 2013-12-13 2016-03-16 賽諾菲公司 EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (en) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
KR102418477B1 (en) 2014-12-30 2022-07-08 한미약품 주식회사 Gluagon Derivatives
KR101661332B1 (en) * 2015-05-28 2016-09-29 (의료)길의료재단 Pharmaceutical composition for treating muscle atrophy comprising glucagon like-peptide-1 receptor agonist
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066142A2 (en) * 1999-04-30 2000-11-09 Bionebraska, Inc. Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066142A2 (en) * 1999-04-30 2000-11-09 Bionebraska, Inc. Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AL-BARAZANJI K A ET AL: "Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats.", OBESITY RESEARCH JUL 2000, vol. 8, no. 4, July 2000 (2000-07-01), pages 317 - 323, XP002565056, ISSN: 1071-7323 *
BABCOCK A M ET AL: "Neurotensin-induced hypothermia prevents hippocampal neuronal damage and increased locomotor activity in ischemic gerbils", BRAIN RESEARCH BULLETIN, ELSEVIER SCIENCE LTD, OXFORD, GB, vol. 32, no. 4, 1 January 1993 (1993-01-01), pages 373 - 378, XP024389182, ISSN: 0361-9230, [retrieved on 19930101] *
BAGGIO L L ET AL: "A Recombinant Human Glucagon-Like Peptide (GLP)-1-Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor-Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis", DIABETES, AMERICAN DIABETES ASSOCIATION, US, vol. 53, 1 September 2004 (2004-09-01), pages 2492 - 2500, XP003004469, ISSN: 0012-1797 *
DATABASE EPO Proteins [online] 24 November 2000 (2000-11-24), "Sequence 8 from Patent WO0066142.", XP002565057, retrieved from EBI accession no. EPOP:AX045426 Database accession no. AX045426 *
DEGN KRISTINE B ET AL: "One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes", DIABETES, AMERICAN DIABETES ASSOCIATION, US, vol. 53, no. 5, 1 May 2004 (2004-05-01), pages 1187 - 1194, XP002512806, ISSN: 0012-1797 *
HAYES MATTHEW R ET AL: "Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation", ENDOCRINOLOGY, vol. 149, no. 8, 17 April 2008 (2008-04-17), pages 4059 - 4068, XP002565048, ISSN: 0013-7227 *
LAWRENCE B ET AL: "NOVEL DAC:GLP-1 ANALOGUE, CJC-1131, EXHIBITS PROLONGED EFFICACY, SAFETY AND TOLERABILITY FOLLOWING SUBCUTANEOUS ADMINISTRATION IN NORMAL AND DIABETIC ANIMALS", DIABETOLOGIA, SPRINGER, BERLIN, DE, vol. 45, no. SUPPL. 02, 1 August 2002 (2002-08-01), pages A213/A214, XP008042635, ISSN: 0012-186X *
O'SHEA DONAL ET AL: "A role for central glucagon-like peptide-1 in temperature regulation", NEUROREPORT, vol. 7, no. 3, 1996, pages 830 - 832, XP009128440, ISSN: 0959-4965 *
SOWDEN GILLIAN L ET AL: "Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor", AMERICAN JOURNAL OF PHYSIOLOGY - REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, vol. 292, no. 2, February 2007 (2007-02-01), pages R962 - R970, XP002565049, ISSN: 0363-6119 *

Also Published As

Publication number Publication date
WO2010013012A9 (en) 2010-08-12
WO2010013012A4 (en) 2010-06-10
WO2010013012A2 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
WO2010013012A3 (en) Hypothermia inducing polypeptides and uses thereof
WO2008033395A3 (en) Melanocortin and transferrin fusion proteins
WO2006097536A3 (en) Dimeric peptide agonists of the glp-1 receptor
WO2010120476A3 (en) N-terminus conformationally constrained glp-1 receptor agonist compounds
NZ627111A (en) Variants of activin iib receptor polypeptides and uses thereof
EP2301962A3 (en) Invention affecting GLP-1 and Exendin
NZ602634A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
HK1200842A1 (en) Proteins with improved half-life and other properties
WO2006074390A3 (en) Methods of treating obesity with combination therapeautics of igf-i fusion polypeptides
NZ732000A (en) Gip and glp-1 co-agonist compounds
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
EP2476698A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
WO2008038287A3 (en) N-terminal fgf variants having increased receptor selectivity and uses thereof
WO2008012629A3 (en) Exendin fusion proteins
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
WO2011024110A3 (en) Glucagon-like peptide-1 receptor (glp-1r) agonists for treating autoimmune disorders
IL199263A (en) Glucagon peptide with improved solubility, a pharmaceutical composition comprising same and uses thereof for the preparation of medicaments
WO2009155258A3 (en) Glucagon/glp-1 receptor co-agonists
EA200901108A1 (en) GLAGON / GLP-1-RECEPTOR COAGONISTS
WO2006121860A3 (en) Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
WO2009058957A3 (en) Intranasal administration of active agents to the central nervous system
TN2012000393A1 (en) Agonist dr5 binding polypeptides
IN2012DN02981A (en)
UA107330C2 (en) Tuberculous protein rv3616c and its application
MX2021000030A (en) Methods and compositions using klotho variant polypeptides.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09784834

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09784834

Country of ref document: EP

Kind code of ref document: A2